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Risk-taking and fairness among 
cocaine-dependent patients in dual 
diagnoses: Schizophrenia and Anti-
Social personality Disorder
Gerardo Sabater-Grande1 ✉, Gonzalo Haro2,4, Aurora García-Gallego1, 
nikolaos Georgantzís1,5, noemí Herranz-Zarzoso1 & Abel Baquero2,3
this study reports experimental results from a clinical sample of patients with a cocaine-related disorder 
and dual diagnosis: Schizophrenia and Anti-Social personality Disorder. Both types of patients as well 
as a non-clinical group of students performed two incentivized decision-making tasks. In the first part 
of the experiment, they performed a lottery-choice task in order to elicit their degree of risk aversion. 
In the second part, they decided in two modified dictator games aimed at eliciting their aversion to 
advantageous and disadvantageous inequality. it is found that the Anti-Social personality Disorder 
group exhibits no significant differences from the non-clinical sample in either task. However, compared 
with the students’ sample, subjects from the group with schizophrenia show more risk aversion and 
exhibit more aversion towards disadvantageous inequality.
Cocaine is the most commonly used illicit stimulant drug in Europe. It is estimated that about 2.3 million young 
adults aged from 15 to 34 (1.9% of this age group in the general population) consumed cocaine during 20171. 
In Spain, cocaine is responsible for the highest share of drug-related cases admitted for treatment (36.5%) and 
it is involved in about half of all reported drug-related emergencies1. Two of the most prevalent comorbid (dual 
pathology) mental disorders in cocaine abusers are schizophrenia and Anti-Social Personality Disorder (ASPD, 
henceforth)2,3.
Schizophrenia is a mental disorder characterized by misinterpretation in thinking processes, especially delu-
sions (beliefs that are not based on reality) and hallucinations (inability to differentiate between what is real and 
what is being produced in the brain). ASPD is a personality disorder characterized by a dominant pattern of 
antisocial behaviors including reckless neglect of own or others’ safety, constant irresponsibility with economic 
obligations, and deception leading to personal gain.
The etiological studies available are aimed at unveiling causal relationships and do not actually allow for an 
advance in the pharmacological treatment of these two pathologies. Interestingly however, the experimental par-
adigm of decision-making processes in mental disorders such as addiction, psychopathy and schizophrenia4 has 
proved to be useful in the design of psychosocial treatments in patients with dual pathology.
Decision-making tasks require the activation of a complex system of cognitions, emotions, and conducts 
directly related to the functionality of everyday life. As5 states, when subjects with different personality disorders 
face decision-making problems, they are strongly affected by concerns related to past experiences. Situations 
involving risk and/or interpersonal comparisons are likely to play an important role in subjects’ decisions.
This paper focuses on the differences between, on one hand, a non-clinical sample and, on the other hand, two 
clinical samples involving cocaine abuse patients: one with schizophrenia and the other with ASPD comorbidi-
ties. Specifically, comparisons across the controls and the clinical samples are made to identify behavioral differ-
ences in the domains of risk and inequality aversion. Following standard terminology, risk aversion is defined as 
the decision maker’s disutility due to the dispersion of possible monetary consequences of uncertain prospects. 
Inequality aversion is a decision maker’s preference for egalitarian distributions of wealth as opposed to having 
more or less than others (advantageous and disadvantageous inequality aversion, respectively, as defined by6).
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Rather than asking subjects about their preferences, incentive-compatible experiments face subjects with the 
real monetary consequences of their choices. The use of such experiments in the study of social preferences 
and fairness is frequently based on two related but distinct two-player paradigms: Dictator Game (DG) and 
Ultimatum Game (UG)7. In DG one of the players (dictator) decides on the shares of both players, while the other 
player passively experiences the consequence of this decision. In UG, the first player decision is a proposal for the 
second player to accept or reject, in which case they both earn nothing. While offers in the UG may also contain 
information on the proposer’s belief on what the second player would accept, offers in the DG are only related to 
the first player’s preference for fairness. The DG is adopted here as the elicitation device for inequality aversion. In 
fact, following8, a modified version of the DG allows us to elicit advantageous inequality aversion. Furthermore, 
we construct a symmetric task to elicit, also, disadvantageous inequality aversion. Finally, in order to simplify 
the task and to facilitate comparability with a larger sample, the number of alternative options available has been 
reduced, without any loss of information. The reason for omitting some options was the fact that, as observed 
in8, less than 5% of relevant choices were made within the range of those options. A further advantage of using 
this modified version of the DG is the salience (payoffs are 30–150 times higher than those in9–11) of the payoffs, 
making relevant for the subjects to carefully consider the consequences of their choices.
To the best of our knowledge,12 is the only previous study associating social decision-making with dual diag-
noses. That paper uses the UG as a social preference elicitation device, and looks into a broader spectrum of per-
sonality disorders (antisocial, obsessive-compulsive, borderline, …). It is found that patients with dual diagnosis 
show poorer emotion recognition than healthy controls.
This paper fills the gap on social preference elicitation among schizophrenia or ASPD patients. We compare 
each one of the clinical cocaine abuse groups (schizophrenia and ASPD) with the non-clinical one.
In related literature, while no significant correlation was found between schizotypal traits and the amount of 
money offered in the DG, patients with schizophrenia appeared to accept more unfair offers than the controls in 
the UG13,14. Furthermore, joint analysis of UG and DG games leads to mixed results15–18 concerning the fairness 
hypothesis (that is, equality between UG and DG offers).
The association between risk aversion and personality disorders has been studied under a plethora of tasks 
and paradigms. Most studies have not used real monetary rewards while using some tasks from the experimental 
economics toolbox like the Balloon Analogue Risk Task (BART)19–21, the Risky-Gains Task22. In general, patients 
are more conservative, leading to suboptimal risky decisions. Contrary to this evidence,23 find that patients with 
schizophrenia reveal an overall riskier performance on the Game of Dice Task24.
The evidence on the relationship between psychopathy and risk aversion is mixed. All possible results have 
been reported. Some find that risk-aversion is increasing25, decreasing26–29 or is not related with psychopathy30,31.
Summing up, we aim at identifying differences between healthy controls and cocaine-dependent comor-
bid patients, in other-regarding (inequality aversion) and individual (risk aversion) decision-making tasks. We 
hypothesize that, generally speaking, schizophrenia and ASPD have effects on the subject’s attitude towards risk 
as well as on other-regarding feelings, not only in absolute, but also in relative terms. There is no clear pattern 
documented by previous research and, thus, no ex-ante clear theoretical expectation regarding the two aforemen-
tioned effects.
Materials and methods
participants and procedures. Our experiment was carried out in two parts. In the first part, 220 under-
graduate students participated in the experimental sessions run in the Laboratorio de Economía Experimental 
(LEE) of the Universitat Jaume I (UJI) in Castellón (Spain). Prior to the experimental session, informed consent 
was obtained from all students acknowledging acceptance of our data management protocols involving ano-
nymity, confidentiality and exclusive use for the present scientific research. During the year 2012 (1 March to 30 
June), the tool ORSEE32 was used to recruit subjects among undergraduate students from different degree courses 
(psychology, economics, business administration, law, etc.) at the U. Jaume I. At the beginning of each session, 
subjects were given written instructions, which were also read aloud by the organizers. Any remaining questions 
were answered privately. We elicited their risk preferences and their (non-) aversion to (dis)advantageous ine-
quality with real monetary incentives. Each session lasted about half an hour and the average payoff was €15.
In the second part, from January 2016 to November 2017, a clinical sample of patients with cocaine-related 
disorder was recruited at the Unit of Addictive Behaviors (UCA), the Hospital Detoxification Unit (UDH) and 
the Severe Dual Pathology Program (PPDG), which are health care resources implemented by the Department 
of Health of Castellón (Spain). Informed consent was obtained from all patients in which they were informed 
that their medical records would be treated with strict confidentiality and would be protected in accordance with 
the current legislation on data protection. The confidentiality of data and participants’ identity was guaranteed. 
This research complied with the guidelines set out in the World Medical Association’s Declaration of Helsinki. 
The Ethical Committee of the Hospital Provincial of Castellón (Spain) approved this research (11/23/2015). The 
entire clinical sample was evaluated and classified by clinical personnel, supervised by medical researchers, in two 
subgroups of patients who met DSM-IV criteria for: (i) cocaine abuse patients with schizophrenia and (ii) cocaine 
abuse patients with ASPD.
The sociodemographic information was collected by means of an admission interview. For the clinical vari-
ables, the Dual Diagnostic Screening Interview (DDSI) was administered, validated specifically for people with 
substance-related disorders in order to exclude patients with diagnoses other than schizophrenia and ASPD. If 
negative, the Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV (PRISM-IV33) was 
used to confirm a cocaine-related disorder, schizophrenia and ASPD. Moreover, for the ASPD evaluation, the spe-
cific Psychopathy List-Revised (PCL-R34) was clinician-administered as a complementary method. The research 
assessments were administered after 7–10 days of detoxification treatment, when psychopathological stabilization 
had been reached. We considered that patients’ capacities for concentration and attention were acceptable to face 
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the incentivized tasks used to elicit risk and inequality aversion. In fact, before performing the tasks, patients 
were trained in the use of the specific software of the experiment. Furthermore, patients were asked several (pilot) 
questions so that the experimenters could be sure that they fully understood the instructions for the experi-
ment. Each patient was individually assisted to ensure full understanding of the instructions and the software. 
Concerning the understanding ability of substance-users,35 find no differences in sustained attention between 
cocaine-users and controls in tasks which are less demanding on working memory, such as ours. Furthermore36–38 
find that ASPD subjects generally perform as well as healthy controls in cognitive measures like planning, atten-
tion, and working memory. Previous results on sustained attention in patients with schizophrenia are mixed39. 
In that sense, although the degree to which schizophrenia patients show intact functioning on decision-making 
tasks is still unclear40,41 (using the Iowa Gambling Test to measure decision-making ability) find performance in 
schizophrenia patients is similar to that of healthy controls.
At the beginning of the experimental session patients were informed that they could opt out of the experiment 
at any time. Finally, the same software and procedures applied for the non-clinical sample were used to elicit risk 
aversion and aversion to (dis)advantageous inequality through incentive-compatible methods for a sample of 
cocaine-abusers consisting of 23 schizophrenia and 23 ASPD patients. Each session lasted about 45 minutes and 
the average payoff was €14. Regarding the question of how patients perceive the incentives,42 states that offering 
monetary incentives significantly improves performance on different cognitive tasks among patients with schiz-
ophrenia. We work under the assumption that this is also valid for patients with ASPD.
A possible source of bias for the observed behavior could be demand effects due to the patients’ willingness to 
comply with uncontrolled perceived rules and, perhaps, the actions they might feel as desirable by the doctors. In 
order to minimize or at least equalize any possible demand effects across the three populations, we ran the exper-
iments in the presence of the same group of experimenters and technical support personnel.
To reduce any biases derived from inter-observer differences, all the diagnostic testing was performed by 
the same research psychologist, who had previously obtained the official training for the PRISM-IV interview. 
In order to maintain confidentiality and reduce possible “experimenter demand effects”, diagnostic tests were 
performed independently of the clinical interviews, and behavioral information was not transmitted to doctors.
Measures. The Sabater-G.-Georgantzis lottery panel task: A measure of risk aversion. As a measure 
of subjects’ risk aversion, we propose a simple task for the elicitation of risk attitudes, initially used in43, the 
Sabater-Grande and Georgantzis (SGG hereafter) lottery panel task, displayed in Table 1. In this task, subjects face 
eight subtasks called panels 1, 2, 3, …, 8, presented in this order on a sequence of decision screens. Each panel 
corresponds to ten lotteries, from which subjects have to choose their preferred one. In panels 1 to 4, each lottery 
is defined by the probability p of winning a prize of €X (else nothing) at no cost. Given that a degenerate lottery of 
a certain (p = 100%) reward (€1) is included, the unfavorable options of all other lotteries (€0) can be considered 
as losses with respect to the €1 certain alternative. Panels 5 to 8 set the certain option to X = €0, ruling out the 
Panel 1
Prob. 1 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1
€ 1 1.1 1.3 1.5 1.7 2.1 2.7 3.6 5.4 10.9
Panel 2
Prob. 1 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1
€ 1 1.2 1.5 1.9 2.3 3 4 5.7 9 19
Panel 3
Prob. 1 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1
€ 1 1.7 2.5 3.6 5 7 10 15 25 55
Panel 4
Prob. 1 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1
€ 1 2.2 3.8 5.7 8.3 12 17.5 26.7 45 100
Panel 5
Prob. 1 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1
€ 0 0.1 0.3 0.5 0.7 1.1 1.7 2.6 4.4 9.9
Panel 6
Prob. 1 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1
€ 0 0.2 0.5 0.9 1.3 2 3 4.7 8 18
Panel 7
Prob. 1 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1
€ 0 0.7 1.5 2.6 4 6 9 14 24 54
Panel 8
Prob. 1 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1
€ 0 1.2 2.8 4.7 7.3 11 16.5 25.7 44 99
Table 1. SGG Lottery Panel Task.
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possibility of losses. By inspection, the farther right subjects choose, the less risk averse they are. For comparabil-
ity of choices across panels, the data analysis uses the winning probability of the lottery chosen.
After responses to this and the subsequent inequality aversion tasks are submitted, subjects earnings from the 
whole experiment are determined. To calculate earnings from the SGG lottery panel task, one of the eight panels 
is randomly picked and each subject’s preferred lottery in it is executed.
In all panels, the winning probability is varied from p = 0.1 to p = 1 in steps of 0.1. Prizes are designed so that, 
within a panel, the expected value of the lotteries increases linearly with the probability of not winning by a con-
stant t over a fixed gain of €1 in panels 1–4, and €0 in panels 5–8. Thus, t is a panel-specific risk premium, which 
generates an increase in the expected values of the lotteries as we move from safer to riskier options within the 
same panel. This parameter is increased from panel 1 to 4 and from 5 to 8. Thus, intuitively, a subject should be 
expected to make riskier choices when moving from panel 1 to 4 and from panel 5 to 8.
DIA and AIA: Testing Aversion to (dis)Advantageous Inequality. We implement two modified dictator games 
to elicit Advantageous Inequality Aversion (AIA) and Disadvantageous Inequality Aversion (DIA). In each task, 
participants play both roles, dictator and recipient, but only one of them is randomly chosen to determine the 
subjects’ final payoffs. The underlying assumption in both tasks is that the dictator’s preferences include two 
components, one for own and one for other’s gains. Due to a qualitative difference between advantageous and 
disadvantageous inequality, two different tasks are used in order to address the relative weight of each player’s 
other-regarding component in each context. With the aim of not inducing a different perception of the two tasks 
due to format heterogeneity, we decided to modify the advantageous inequality task in8 to create the disadvanta-
geous inequality one.
In the version AIA displayed in Table 2, the dictator has to decide which part of the payoff of €15 (if any) is 
willing to give to the partner, then achieving a more equal distribution of payoffs. More specifically, in AIA sub-
jects are given two lists of 16 payoff vectors where the first (second) element of each payoff vector corresponds to 
the dictator’s (recipient’s) payoff. Observe in Table 2 that the left-hand side payoff vector contains equal payoffs 
for both subjects varying from (€15, €15), (€14, €14) up to (€0, €0), whereas the right-hand side payoff vector 
is always (€15, €0). Subjects were asked to choose at which point, if any, they preferred to switch from the left 
to the right payoff vector. For the sake of consistency, participants were not allowed to switch back and forth. 
Therefore, inconsistent preferences were avoided with a concave utility function, given that the egalitarian out-
come is “cheaper” for any decision beyond the switching point (SP). Specifically, for this task a SP value of “0” 
indicates that the subject prefers the left-hand side payoff to the outcome (€15, €0) in all cases considered. At the 
other extreme, a SP of “16” denotes a situation in which the subject prefers the outcome (€15, €0) to the egalitar-
ian payoffs in all cases considered. In intermediate positions, a SP of “1” indicates that the subject always prefers 
the egalitarian payoffs to (€15, €0) except when the outcome is (€0, €0). A SP of “2” denotes a preference for all 
the egalitarian payoffs to (€15, €0) except for outcomes (€0, €0) and (€1, €1), and so on and so forth. We use the 
SP ranging from 0 to 16 in order to elicit a parameter of aversion to advantageous inequality. Using the utility 
function of6, like8 we calculate point estimates of the subjects’ AIA parameter (β). Given that the right-hand payoff 




The lower the SP, the higher the value of β is, and, therefore, the higher the aversion to advantageous inequal-
ity. In the data analysis, the SP is used as the advantageous inequality score.
Row My gains Partner’s gains My gains Partner’s gains
1 €15 €15 €15 €0
2 €14 €14 €15 €0
3 €13 €13 €15 €0
4 €12 €12 €15 €0
5 €11 €11 €15 €0
6 €10 €10 €15 €0
7 €9 €9 €15 €0
8 €8 €8 €15 €0
9 €7 €7 €15 €0
10 €6 €6 €15 €0
11 €5 €5 €15 €0
12 €4 €4 €15 €0
13 €3 €3 €15 €0
14 €2 €2 €15 €0
15 €1 €1 €15 €0
16 €0 €0 €15 €0
Table 2. Advantageous Inequality Aversion (AIA) task.
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In the version DIA, displayed in Table 3, the left-hand side of the payoff vector contains identical equal payoffs 
to those contained in the AIA, but the right-hand side consists always in the pair of payoffs (€0, €15). Subjects are 
asked to choose at which point, if any, they prefer to switch from the left to the right-hand side pair of payoffs.
For this task, a SP value of “0” would indicate that the subject prefers the egalitarian payoffs to the outcome 
(€0, €15) in all cases. In the other extreme, a SP of “16” corresponds to a subject who always prefers the outcome 
(€0, €15) to any of the egalitarian ones. In intermediate positions, a SP of “1” indicates that the subject prefers the 
egalitarian payoffs to (€0, €15) in all cases except when the outcome is (€0, €0). A SP of “2” denotes a preference 
for all the egalitarian payoffs to (€0, €15) except for outcomes (€0, €0) and (€1, €1), and so on and so forth. It 
is worth mentioning that the only reason for a subject to choose the right-hand side options is a willingness to 
sacrifice his/her own payoff to increase the partner’s payoff, representing a subject’s kind of generosity. We use 
the SP ranging from 0 to 16 with the aim of calculating the parameter of aversion to disadvantageous inequality, 




Observe that the lower the value of SP, the higher the level of aversion to disadvantageous inequality is, corre-
sponding to a higher value of α. The SP is used as the disadvantageous inequality score in the data analysis.
Substance use and mental disorders. Dual diagnosis screening interview (DDSI). The Dual Diagnosis 
Screening Instrument (DDSI) was designed by44 to screen psychiatric disorders in substance abusers in 
with-treatment and without-treatment seeking samples. The DDSI has shown a valid and easy-to-administer 
screening tool for detecting possible psychiatric comorbidities among substance abusers. Specifically, the DDSI 
has a high sensitivity (≥80%) for identifying lifetime depression, mania, psychosis, panic, social phobia, and 
specific phobia disorders, being higher than or equal to 82% for those diagnoses. A test-retest κ shows excellent 
agreement: range 81%–95%. Patients with a positive diagnosis other than schizophrenia or ASPD applying this 
screening are excluded from the study.
Psychiatric Research Interview for Substance and Mental Disorders version IV (PRISM-IV). The PRISM-IV 
was developed by33 as a semi-structured clinician-administered interview with the purpose of measuring the 
major Axis I DSM-IV diagnoses (current and past) of alcohol, drug and psychiatric disorders. It was designed 
to provide clear guidelines for differentiating among the expected effects of intoxication and withdrawal, 
substance-induced disorders, and primary disorders. The PRISM-IV also covers two Axis II disorders: Borderline 
Personality Disorder and Antisocial Personality Disorder.
Although primarily designed as a research instrument, the PRISM-IV provides coverage of alcohol- and 
drug-related experiences and symptoms that may be relevant in identifying areas of focus for medical treatment. 
The interview is used to include subjects within one of two groups: (i) schizophrenia and cocaine-related disorder, 
and (ii) ASPD and cocaine-related disorder. PRISM-IV is also applied to describe the different substance-related 
disorders, as well as to confirm cocaine-related disorders.
PCL-R: A Psychopathy test. The PCL-R (Psychopathy Checklist-Revised) is a 20-item measure of psychopa-
thy designed by33. The items are rated on a 3-point scale (0 = item does not apply, 1 = item applies somewhat, 
2 = item definitely applies). The items are summed to yield total scores, ranging from 0 to 40, reflecting the 
degree to which an individual resembles the prototypical psychopath. A cutoff score of 17 was used to con-
firm the presence of at least moderate psychopathy. The two-factor PCL-R model was used in order to examine 
Row My gains Partner’s gains My gains Partner’s gains
1 €15 €15 €0 €15
2 €14 €14 €0 €15
3 €13 €13 €0 €15
4 €12 €12 €0 €15
5 €11 €11 €0 €15
6 €10 €10 €0 €15
7 €9 €9 €0 €15
8 €8 €8 €0 €15
9 €7 €7 €0 €15
10 €6 €6 €0 €15
11 €5 €5 €0 €15
12 €4 €4 €0 €15
13 €3 €3 €0 €15
14 €2 €2 €0 €15
15 €1 €1 €0 €15
16 €0 €0 €0 €15
Table 3. Disadvantageous Inequality Aversion (DIA) task.
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subcomponents of psychopathy: Factor 1 (F1) assesses affective-interpersonal traits, while Factor 2 (F2) measures 
antisocial-impulsive traits. Extensive research attests to the reliability and validity of PCL-R total and factor scores 
as measures of psychopathy.
Sociodemographic composition of the samples. This section includes a description of the sociodemo-
graphic characteristics of the samples under analysis. Concerning average age, subjects in the non-clinical sample 
are 21.9 years old (SD = 2.9), 39.4 years old (SD = 8.5) in the schizophrenia sample, and 43 years old (SD = 5.5) 
in the ASPD sample. With respect to gender, the share of males is 37.7% in the non-clinical sample, 95.2% in the 
schizophrenia sample and 95.7% in the ASPD sample. The non-clinical sample was randomly formed by volun-
teers responding to a public call, according to usual recruitment experimental protocols. As for the clinical sample, 
it was formed by volunteers recruited among the patients under treatment available over a two-year period, lead-
ing to a gender-unbalanced composition.
Focusing on other relevant sociodemographic characteristics, 52.2% of our patients with schizophrenia and 
65.2% with ASPD have a family history of addictions. Patients started consuming cocaine at an average age of 
18.7 years (SD = 4.1) for the schizophrenia sample and 18.8 years (SD = 6.2) for the ASPD sample, and developed 
a cocaine-related disorder at the age of 20.1 years (SD = 4.5) for the schizophrenia and 20.3 (SD = 7.2) for the 
ASPD groups respectively. The mean score on the cocaine severity index is 7.9 (SD = 2.7) for the schizophrenia 
group, and 8.0 (SD = 1.6) for the ASPD.
The percentage of patients with alcohol-related disorder is 65.2% for the schizophrenia group, and 47.8% 
for the ASPD. Moreover, 73.9% of the schizophrenia sample and 68.2% of the ASPD, have a cannabis-related 
disorder. The cocaine and other substances consumption were similar among patients with schizophrenia and 
ASPD, except for heroin, used by 13% of patients with schizophrenia against 86.4% in the ASPD group (X2 = 
24.2; p < 0.001). Furthermore, 52.2% of the schizophrenia sample and 34.8% of the ASPD has a family history of 
mental illness.
Important differences are found in the psychopathological assessment. Namely, patients with ASPD scored 
higher than patients with schizophrenia on the total PCL-R score (Mean Difference [MD] = 26.2; p < 0.001), 
with significant differences in all the facets and factors of the PCL. Finally, schizophrenia patients had a higher 
incidence of suicide attempts than the ASPD group (47.8% vs. 30.4%; X2 = 5.7; p = 0.017).
Data analysis and results. We present our analysis by task, explaining our empirical strategy. First, for the 
risk task the variable used is the probability of the lottery chosen in each panel. Second, for the aversion to (dis)
advantageous inequality task, the variable used is the SP between the (altruist) selfish and the egalitarian choice. 
For each variable, we present descriptive statistics. When reported, correlation between variables refers to the 
non-parametric pairwise Spearman correlation.
Normality of the corresponding distributions is tested using the Shapiro–Wilk test. When normality is 
rejected, a Mann-Whitney (M-W) test is used to assess the significance of differences across the non-clinical 
and the clinical samples. The M-W test compares mean ranks and, in the case of identically shaped distributions 
(checked by a Kolmogorov-Smirnov test), is a test of medians.
The clinical and non-clinical samples are demographically different. We have checked whether differences 
in gender composition and age are responsible for the differences in behavior. With respect to gender, random 
control samples of similar composition with that of the clinical group have been generated. To do this, all possible 
combinations of four different females (21 groups of 4) were matched with 21 groups of 84 males formed by ran-
domly skipping one, two or three males of the non-clinical sample. This is equivalent to any random extraction of 
the 17.44*1044 88-subject possible samples, that can be formed from the non-clinical population with an identical 
gender composition as that of the clinical sample. To account for possible confounding effects of age in our clini-
cal vs non-clinical behavioral differences, we have performed OLS regression analysis whose results are reported 
in Table 6. The interference of age differences across clinical and non-clinical samples in the reported behavioral 





(N = 23) ASPD (N = 23) Comparisons non clinical vs.





Panel 1 0.48 0.25 0.61 0.23 0.53 0.34 2.371** 0.323
Panel 2 0.43 0.20 0.65 0.19 0.41 0.26 4.606*** −0.909
Panel 3 0.42 0.20 0.56 0.23 0.46 0.27 2.940*** 0.644
Panel 4 0.40 0.21 0.58 0.22 0.41 0.27 3.346*** −0.100
Panel 5 0.54 0.28 0.62 0.22 0.43 0.31 1.045 −1.555
Panel 6 0.50 0.27 0.56 0.27 0.45 0.28 1.047 −0.868
Panel 7 0.48 0.25 0.69 0.22 0.47 0.27 3.581*** −0.033
Panel 8 0.44 0.23 0.57 0.24 0.45 0.27 2.332** 0.228
Table 4. Descriptive statistics and M-W tests comparisons of SGG lottery panel task. Median and Standard 
Deviation corresponding to probabilities (SGG prob.) chosen by subjects in each panel of the SGG lottery panel 
task; (last two columns) M-W test U values. Significance values: *p < 0.1; **p < 0.05; ***p < 0.01.
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Risk task results. Descriptive statistics. Table 4 presents descriptive statistics (mean and standard devi-
ation) corresponding to the SGG lottery panel task for the three samples: non-clinical subjects, patients with 
schizophrenia, and patients with ASPD.
Whereas choices by the non-clinical and the ASPD samples are on average below 0.5 in most panels, patients 
with schizophrenia choose, on average, lotteries well above 0.5 in all panels. This indicates that cocaine abuse 
patients with schizophrenia are more risk averse than cocaine abuse patients with ASPD.
Statistical test comparisons. The distributions of choices in the SGG lottery panel test are presented in Figs. 1 and 
2. Specifically, Fig. 1 shows the distributions of choices in panels 1 to 4, and Fig. 2 presents the choices in panels 
5 to 8.
The Shapiro–Wilk test rejects normality for the risk aversion data in the non-clinical sample. Figures 1 and 2 
show that for four (out of the total of eight) panels in the SGG lottery panel task, there are significant differences 
(Kolmogorov-Smirnov test) between the distributions of choices made by cocaine abuse patients with schizo-
phrenia and the non-clinical sample. Given that no significant differences are found between the distributions 
of choices made by non-clinical subjects and cocaine abuse patients with ASPD, the corresponding comparisons 
using the M-W test will be attributed to median risk scores.
Figure 1. Distributions of choices in panels 1 to 4 of the SGG lottery panel task for non-clinical subjects, 
patients with schizophrenia and with ASPD. Kolmogorov-Smirnov significance values: *p < 0.10; **p < 0.05; 
***p < 0.01.
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Table 4 shows that for most panels of the SGG lottery panel task, with the exception of panels 5 and 6, the 
cocaine abuse patients with schizophrenia exhibit a significantly higher risk aversion mean rank than the 
non-clinical sample. This implies less risky behavior by the patients with schizophrenia, independently of the 
risk premium offered. However, when comparing the ASPD patients’ median risk aversion with the non-clinical 
sample, no significant differences are found.
Throughout the sample, no significant correlation (Spearman) is obtained between risk and social preferences 
elicitation tasks. Thus, we can proceed with the analysis of social preferences independently of risk preferences.
AiA and DiA tasks results. Descriptive statistics. Table 5 shows descriptive statistics (mean SP, and stand-
ard deviation) corresponding to the AIA and DIA tasks for non-clinical subjects, patients with schizophrenia, and 
patients with ASPD.
Data from the AIA test yield SP means within the (10, 11) interval for all groups, clinical and non-clinical. This 
evinces that subjects are willing to sacrifice an average amount between €5 and €6 of their €15 payoff, in order to 
reach an outcome in which the partner earns between €9 and €10.
For the non-clinical and the ASPD samples, data from the DIA test yield similar mean SP as the AIA test. 
Observe that, on average, in order to keep egalitarian earnings of €9, non-clinical subjects are willing to reduce 
the partner’s payoff by €6. However, cocaine abuse patients with schizophrenia are willing to reduce the partner’s 
Figure 2. Distributions of choices in panels 5 to 8 of the SGG lottery panel task for non-clinical subjects, 
patients with schizophrenia and patients with ASPD. Kolmogorov-Smirnov significance values: *p < 0.10; 
**p < 0.05; ***p < 0.01.
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payoff between €8 and €9 in order to reach an egalitarian outcome oscillating between €6 and €7. Therefore, on 
average, the exchange rate between the other’s and one’s own payoff for cocaine abuse patients with schizophrenia 
almost doubles the corresponding exchange rate of the other two samples, the non-clinical and the cocaine abuse 
patients with ASPD.
Statistical test comparisons. Figure 3 displays the distributions of choices corresponding to AIA and DIA. Like 
in the risk task, the Shapiro–Wilk test shows that choices in these two tests are not normally distributed for 
the non-clinical sample. Significant differences are obtained between the distributions of DIA of cocaine abuse 
patients with schizophrenia and the non-clinical subjects.
Observe in Table 5 that cocaine abuse patients with schizophrenia exhibit a significantly higher DIA mean 
rank than the non-clinical sample. However, no significant differences are found for DIA between cocaine abuse 
patients with ASPD and the non-clinical sample. Regarding AIA scores, no statistically significant differences are 
found between healthy controls and the clinical sample.
The present study has potential limitations concerning the sample size, possible confounding factors (subjects’ 
IQ, years of education, etc.), and the control group (young students). Regarding the relatively small sample size, 
and in order to check whether some the lack of significance for some differences was due to a low statistical power, 
we conduct an ex-post power analysis using Stata with power set at 0.80 and probability at 0.05. In our case, sam-
ple sizes for ASPD subjects and patients with schizophrenia would have to increase to at least N = 74 and 107, 
respectively, in order for group differences to reach statistical significance at the 0.05 level. As far as the control 
group is concerned, significant divergence in gender and age exists between the control group and the clinical 




= 23) ASPD (N = 23)
Mean rank comparisons non 
clinical vs.
SP M SD M SD M SD Schizophrenia ASPD
AIA 10.30 3.78 10.04 4.83 10.74 5.46 0.213 −0.938
DIA 11.31 4.92 6.39 6.29 9.00 6.42 0.001** −0.962
Table 5. Descriptive statistics and M-W tests comparisons of the AIA and DIA tasks. Median and Standard 
Deviation corresponding to the switching point (SP) of subjects in the AIA (Advantageous Inequality Aversion) 
and the DIA (Disadvantageous Inequality Aversion) tasks. ASPD: Anti-Social Personality Disorder; (columns 
7–8) Mann-Whitney test U values. Significance values: *p < 0.1; **p < 0.05; ***p < 0.01.
Figure 3. Choice distributions in AIA and DIA for non-clinical subjects, patients with schizophrenia and 
patients with ASPD. Kolmogorov-Smirnov test significance values: *p < 0.1; **p < 0.05; ***p < 0.01.
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gender, we have generated random non-clinical samples with the same gender proportion as the clinical one. The 
analysis performed based on these samples supports the robustness of the results. With respect to age discrepan-
cies between clinical samples and controls, the robustness check has been twofold. First, using Spearman corre-
lation, we find that age is not significantly correlated with the choices in the tasks. Second, in Table 6 we present 
regression analysis in which age has been used as an explanatory variable, obtaining non-significant effects on 
either risk or social preferences. With respect to risk, similar results have been obtained for young and midlife 
adults45 and for a larger random sample by46 who adopt the same risk task. With respect to social preferences, an 
insignificant age effect was also reported by47,48.
A plethora of other uncontrolled factors may partially be responsible for some of the differences reported here. 
Thus, our results have to be taken with caution when establishing causal relationships between the underlying 
pathologies and behavioral patterns of this study. Further research is needed to identify the direct or moderating 
effects of other socioeconomic factors. Given the difficulty in recruiting patient samples and performing behavio-
ral experiments under the desirable conditions, the task of identifying all possible causal relationships is far from 
an easy one.
Discussion
Cocaine consumers initially use the drug as an escape from personal and professional troubles49, thus, as a means 
of mood self-regulation. However, cocaine dependence is often (about 50% of cases) accompanied by mental 
health disorders50, schizophrenia and ASPD being the two most commonly co-occurring. We have hypothesized 
that, among the consequences of these comorbidities, non-transitory effects may be observed on risk-taking 
behavior and social preferences.
We address this hypothesis with data obtained in an incentivized economic experiment. Contrary to previous 
research51, no relation is found between the two domains of behavior studied here: risk and social preferences. 
Following standard economic theory, it is expected that risk and social preferences elicitation tasks to be inde-
pendent. Thus, the relationship reported by51 must be attributed to the gamble-choice task52. To the best of our 
knowledge, this is the first study adopting a standard, incentivized lottery choice task, in order to elicit attitudes 
toward risk in clinical subjects with a dual diagnosis of either schizophrenia or ASPD. Hence, it is also the first 
to report, in an incentivized context, higher degrees of risk aversion associated with schizophrenia, but not with 
ASPD. The lack of ASPD effects on risk attitudes is in line with53.
Regarding the behavior domain of social preferences, it is found that they are also affected by schizophrenia. 
Specifically, we find that cocaine abuse patients with schizophrenia exhibit a higher aversion to disadvantageous 
inequality compared to the non-clinical sample.
Our results contrast with previous literature that reports either the contrary effect (10,11 with, and8,54 without 
monetary incentives), or no effect at all (13,55, using UG). This divergence with previous results may be due to 
differences in the elicitation method. However, it is also true that the perceived persecution and suspicious hyper-
vigilance in schizophrenia56,57 may lead to an increased sensitivity towards unfavorable inequality.
concluding remarks. This study reports results on an incentivized experiment designed to elicit risk and 
social preferences of patients with a cocaine-related disorder and dual diagnosis (Schizophrenia and ASPD) and 
a non-clinical sample. The ASPD group exhibits no significant differences from the non-clinical sample, whereas 
the group with schizophrenia shows a higher aversion to risk and to disadvantageous inequality.
Our study offers a unique opportunity to compare healthy controls with cocaine abuse ASPD patients, 
as well as with cocaine abuse patients with schizophrenia. In terms of clinical treatment, the two groups are 
Average probability chosen 
(Av. individual risk-taking) AIA AIA DIA
ASPD −0.043 −2.468 −6.456 2.443
(0.061) (1.591) (7.114) (2.077)
Schizophrenia 0.115** −2.712* −4.180 5.025***
(0.055) (1.426) (4.589) (1.860)
Age 0.002 0.138** 0.099 −0.008





Constant 0.429*** 7.255*** 8.111*** 4.903***
(0.054) (1.398) (2.066) (1.825)
Observations 262 262 262 262
R-squared 0.068 0.020 0.022 0.074
Table 6. Regression analysis: testing for age effects. OLS Regression coefficients: risk-taking, AIA and 
DIA models. Explanatory variables: ASPD, Schizophrenia, age, and interaction effects. Standard errors in 
parentheses. Significance values: ***p < 0.01, **p < 0.05, *p < 0.1. Supplementary material. Data in Brief. 
Instructions to experimental subjects.
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fundamentally different, since the former cannot be automatically considered to suffer from a treatable dis-
ease, while the other can. Furthermore, the relevance in knowing more about the risk and inequality aversion of 
cocaine abuse patients with schizophrenia may directly affect the mental health professionals' evaluation when 
facing judicial applications for the legal incapacitation of those patients to freely manage their money and to own 
property in general. On the contrary, cocaine abuse ASPD patients are not subject to such evaluations, since their 
competence in such duties is not under scrutiny by the law.
The differences reported here add evidence in favor of the differential therapeutic attitude adopted so far. An 
antisocial person may show levels of risk and inequality aversion similar to healthy individuals, whereas patients 
with schizophrenia are different from non-clinical subjects in both risk and aversion to disadvantageous inequal-
ity. Our approach also serves as proof of the potential added-value of behavioral and experimental economics in 
the study of different psychopathologies.
While we are still far from providing mental health professionals with a definite and reliable tool for differen-
tial diagnoses, our study shows that behavioral economics can be added as a valuable instrument to the complex 
toolbox of mental health professionals. More studies like ours will be needed before we can reach a full map with 
clear borders between different mental conditions.
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